Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia

References

• Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Briganti A, Suardi N, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011;52(8):507–516.
   PubMedGoogle Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–1216.
   PubMed Web of Science ®Google Scholar
• Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 2008;9(4):272–278.
   PubMedGoogle Scholar
• Sharifi N. Steroid receptors aplenty in prostate cancer. N Engl J Med. 2014;370(10):970–971.
   PubMed Web of Science ®Google Scholar
• Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179(4):1235–1242.
   PubMed Web of Science ®Google Scholar
• Hendriksen PJM, Dits NFJ, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006;66(10):5012–5020.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008;102 Suppl 2:13–17.
   PubMed Web of Science ®Google Scholar
• Chapple C. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol. 2010;20(1):43–48.
   PubMed Web of Science ®Google Scholar
• Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology. 2003;62(3 Suppl 1):24–33.
   PubMed Web of Science ®Google Scholar
• Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–1566.
   PubMed Web of Science ®Google Scholar
• Russo A, La Croce G, Capogrosso P, et al. Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opin Pharmacother. 2014;15(16):2319–2328.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–1109.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Salonia A, Briganti A, et al. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013;67(6):544–551.
   PubMed Web of Science ®Google Scholar
• Pagano E, Laudato M, Griffo M, et al. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014;28(7):949–955.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62(10):1547–1559.
   PubMed Web of Science ®Google Scholar
• Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002;2:14.
   PubMedGoogle Scholar
• Sun J, Xiang H, Yang LL, et al. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia. Curr Med Chem. 2011;18(23):3576–3589.
   PubMed Web of Science ®Google Scholar
• Wu C, Kapoor A. Dutasteride for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2013;14(10):1399–1408.
   PubMed Web of Science ®Google Scholar
• Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;10:CD006015.
   Google Scholar
• Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008;77(10):1403–1410.
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81–90.
   PubMed Web of Science ®Google Scholar
• Gravas S, Bach T, Bachmann A, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Eur Assoc Urol. 2015.
   Web of Science ®Google Scholar
• Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42–53.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280(18):1604–1609.
   PubMed Web of Science ®Google Scholar
• Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48(1):12–20.
   PubMed Web of Science ®Google Scholar
• Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med. 2001;67(6):489–500.
   PubMed Web of Science ®Google Scholar
• McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am J Med. 2005;118(12):1331–1339.
   PubMed Web of Science ®Google Scholar
• Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557–566.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112(4):432–441.
   PubMed Web of Science ®Google Scholar
• Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology. 1998;51(6):1003–1007.
   PubMed Web of Science ®Google Scholar
• Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate. 1999;38(3):208–215.
   PubMed Web of Science ®Google Scholar
• Oki T, Suzuki M, Nishioka Y, et al. Effects of saw palmetto extract on micturition reflex of rats and its autonomic receptor binding activity. J Urol. 2005;173(4):1395–1399.
   PubMed Web of Science ®Google Scholar
• Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37(2):77–83.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Thareja S, Verma A, et al. An overview on 5alpha-reductase inhibitors. Steroids. 2010;75(2):109–153.
   PubMed Web of Science ®Google Scholar
• Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 2000;37(4):367–380.
   PubMed Web of Science ®Google Scholar
• Drury JE, Di Costanzo L, Penning TM, et al. Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J Biol Chem. 2009;284(30):19786–19790.
   PubMed Web of Science ®Google Scholar
• Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocr Metab. 2004;89(5):2179–2184.
   PubMed Web of Science ®Google Scholar
• Palin MF, Faguy M, LeHoux JG, et al. Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity. Endocrine. 1998;9(1):65–69.
   PubMed Web of Science ®Google Scholar
• Breu W, Hagenlocher M, Redl K, et al. [Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism]. Arzneimittelforschung. 1992;42(4):547–551.
   PubMed Web of Science ®Google Scholar
• Latil A, Libon C, Templier M, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110(6 Pt B):E301–E307.
   PubMedGoogle Scholar
• Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996;27(7):668–675.
   PubMed Web of Science ®Google Scholar
• Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate. 2000;45(3):259–266.
   PubMed Web of Science ®Google Scholar
• Iii Colado-Velazquez J, Mailloux-Salinas P, Medina-Contreras J, et al. Effect of Serenoa repens on oxidative stress, inflammatory and growth factors in obese wistar rats with benign prostatic hyperplasia. Phytother Res. 2015;29(10):1525–1531.
   PubMed Web of Science ®Google Scholar
• Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr. 2004;58(3):391–402.
   PubMed Web of Science ®Google Scholar
• Schrauzer GN. The nutritional significance, metabolism and toxicology of selenomethionine. Adv Food Nutr Res. 2003;47:73–112.
   PubMedGoogle Scholar
• Ellis DR, Salt DE. Plants, selenium and human health. Curr Opin Plant Biol. 2003;6(3):273–279.
   PubMed Web of Science ®Google Scholar
• Gramm HJ, Kopf A, Bratter P. The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. J Trace Elem Med Biol. 1995;9(1):1–12.
   PubMed Web of Science ®Google Scholar
• Zimmermann MB, Kohrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid. 2002;12(10):867–878.
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K, Das A, Narayanan B, et al. Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer. Carcinogenesis. 2006;27(7):1369–1376.
   PubMed Web of Science ®Google Scholar
• Clark LC, Combs GF Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957–1963.
   PubMed Web of Science ®Google Scholar
• Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90(16):1219–1224.
   PubMed Web of Science ®Google Scholar
• Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005;116(2):182–186.
   PubMed Web of Science ®Google Scholar
• Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64(4):527–542.
   PubMed Web of Science ®Google Scholar
• Barrera LN, Cassidy A, Johnson IT, et al. Epigenetic and antioxidant effects of dietary isothiocyanates and selenium: potential implications for cancer chemoprevention. Proc Nutr Soc. 2012;71(2):237–245.
   PubMed Web of Science ®Google Scholar
• Sies H, Stahl W. Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am J Clin Nutr. 1995;62(6Suppl):1315S–1321S.
   Google Scholar
• Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys. 1989;274(2):532–538.
   PubMed Web of Science ®Google Scholar
• Clinton SK, Emenhiser C, Schwartz SJ, et al. cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996;5(10):823–833.
   PubMed Web of Science ®Google Scholar
• Palan P, Naz R. Changes in various antioxidant levels in human seminal plasma related to immunoinfertility. Arch Androl. 1996;36(2):139–143.
   PubMed Web of Science ®Google Scholar
• Goyal A, Delves GH, Chopra M, et al. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes. BJU Int. 2006;98(4):907–911.
   PubMed Web of Science ®Google Scholar
• Bowen P, Chen L, Stacewicz-Sapuntzakis M, et al. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med. 2002;227(10):886–893.
   Web of Science ®Google Scholar
• Siler U, Barella L, Spitzer V, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J. 2004;18(9):1019–1021.
   PubMed Web of Science ®Google Scholar
• Ford NA, Erdman JW Jr. Are lycopene metabolites metabolically active? Acta Biochim Pol. 2012;59(1):1–4.
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr. 2005;135(8):2030S–2031S.
   Google Scholar
• Herzog A, Siler U, Spitzer V, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J. 2005;19(2):272–274.
   PubMedGoogle Scholar
• Gerster H. The potential role of lycopene for human health. J Am Coll Nutr. 1997;16(2):109–126.
   PubMed Web of Science ®Google Scholar
• Huang CS, Liao JW, Hu ML. Lycopene inhibits experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice. J Nutr. 2008;138(3):538–543.
   PubMed Web of Science ®Google Scholar
• Clinton SK. Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev. 1998;56(2 Pt 1):35–51.
   PubMed Web of Science ®Google Scholar
• Ford NA, Elsen AC, Zuniga K, et al. Lycopene and apo-12ʹ-lycopenal reduce cell proliferation and alter cell cycle progression in human prostate cancer cells. Nutr Cancer. 2011;63(2):256–263.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87(23):1767–1776.
   PubMed Web of Science ®Google Scholar
• Bonvissuto G, Minutoli L, Morgia G, et al. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology. 2011;77(1):248e9–16.
   Web of Science ®Google Scholar
• Altavilla D, Bitto A, Polito F, et al. The combination of Serenoa repens, selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth. J Urol. 2011;186(4):1524–1529.
   PubMed Web of Science ®Google Scholar
• Gerstenbluth RE, Seftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol. 2002;167(5):2267–2270.
   PubMed Web of Science ®Google Scholar
• Itoh N, Patel U, Skinner MK. Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells. Endocrinology. 1998;139(3):1369–1377.
   PubMed Web of Science ®Google Scholar
• Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8(1):11–31.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Tortora G, D’Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8(11):3438–3444.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wu J, Zhu X, et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer. 2007;121(9):2095–2104.
   PubMed Web of Science ®Google Scholar
• Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol. 1996;271(6 Pt 2):H2520–H2528.
   Google Scholar
• Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997;157(6):2323–2328.
   PubMed Web of Science ®Google Scholar
• Galban S, Brady GF, Duckett CS. Caspases and IAPs: a dance of death ensures cell survival. Mol Cell. 2008;32(4):462–463.
   PubMed Web of Science ®Google Scholar
• Mantovani F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol Nefrol. 2010;62(4):335–340.
   PubMed Web of Science ®Google Scholar
• Azimi H, Khakshur AA, Aghdasi I, et al. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets. 2012;11(3):207–221.
   PubMedGoogle Scholar
• Bertaccini A, Giampaoli M, Cividini R, et al. Observational database Serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project. Arch Ital Urol Androl. 2012;84(3):117–122.
   PubMedGoogle Scholar
• Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93(6):751–756.
   PubMed Web of Science ®Google Scholar
• Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;2:CD001423.
   Google Scholar
• Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344–1351.
   PubMed Web of Science ®Google Scholar
• MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012;109(12):1756–1761.
   PubMed Web of Science ®Google Scholar
• Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29(4):231–240; discussion 41–42.
   PubMed Web of Science ®Google Scholar
• Sinescu I, Geavlete P, Multescu R, et al. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int. 2011;86(3):284–289.
   PubMed Web of Science ®Google Scholar
• Pytel YA, Vinarov A, Lopatkin N, et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther. 2002;19(6):297–306.
   PubMed Web of Science ®Google Scholar
• Morgia G, Russo GI, Voce S, et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate. 2014;74(15):1471–1480.
   PubMed Web of Science ®Google Scholar
• Morgia G, Mucciardi G, Gali A, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int. 2010;84(4):400–406.
   PubMed Web of Science ®Google Scholar
• Morgia G, Cimino S, Favilla V, et al. Effects of Serenoa repens, selenium and lycopene (Profluss(R)) on chronic inflammation associated with benign prostatic hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. Int Braz J Urol. 2013;39(2):214–221.
   PubMed Web of Science ®Google Scholar
• Gagnier JJ, Boon H, Rochon P, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134–1149.
   PubMed Web of Science ®Google Scholar
• Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Safety. 2009;32(8):637–647.
   PubMed Web of Science ®Google Scholar
• Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre. 2012;21(5):404–428.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther. 2003;74(6):536–542.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89–100.
   PubMed Web of Science ®Google Scholar
• Roehrborn CK, Noble S, Lucia W, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. AUA meeting 2005; abstract 1277.
   Google Scholar